Lourdes Toral‐Barza

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer.

Ker Yu, Lourdes Toral‐Barza, Carolyn Discafani et al. · Endocrine Related Cancer · 2001 · 418 citations · Full text

Breast Oncology, Cell Cycle, Cancer Biology +16

Biochemical, Cellular, and <i>In vivo</i> Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin

Ker Yu, Lourdes Toral‐Barza, Celine Shi et al. · Cancer Research · 2009 · 326 citations

Chemoprevention Strategy, Cellular Pharmacology, Selective Inhibitors +22

Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy

Christina H. Eng, Zuncai Wang, Diane Tkach et al. · Proceedings of the National Academy of Sciences · 2015 · 221 citations · Full text

Kras Mutant Tumors, Autophagy Inhibitors, Immunology +17

Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2

Ker Yu, Celine Shi, Lourdes Toral‐Barza et al. · Cancer Research · 2010 · 208 citations · Full text

Antitumor Activity, Chemoprevention Strategy, Pharmacotherapy +22

Requirement of the mTOR Kinase for the Regulation of Maf1 Phosphorylation and Control of RNA Polymerase III-dependent Transcription in Cancer Cells

Boris Shor, Jiang Wu, Quazi Shakey et al. · Journal of Biological Chemistry · 2010 · 183 citations · Full text

Tumor Biology, Transcriptional Regulation, Signaling Pathway +13